Effect of platelet-rich fibrin on cell proliferation, migration, differentiation, inflammation, and osteoclastogenesis: a systematic review of in vitro studies

Franz-Josef Strauss1,2 · Jila Nasirzade 1 · Zahra Kargarpoor1 · Alexandra Stähli1,3 · Reinhard Gruber1,3,4

Received: 6 August 2019 / Accepted: 13 November 2019 / Published online: 26 December 2019
© The Author(s) 2019

Abstract
Objective To systematically assess the effects of platelet-rich fibrin (PRF) on in vitro cellular behavior.
Methods A systematic electronic search using MEDLINE database was performed. In vitro studies using PRF were considered and articles published up to June 31, 2018 were screened. Eligible studies were selected based on the use of human PRF.
Results In total, 1746 titles were identified with the search terms, from these 37 met the inclusion criteria and were chosen for data extraction. In addition, 16 new studies, mainly published in 2019, were also included in the analysis resulting in 53 studies. No meta-analysis could be performed due to the heterogeneity of study designs. Included studies show that PRF enhances proliferation, migration, adhesion, and osteogenic differentiation on a variety of cell types along with cell signaling activation. Furthermore, PRF reduces inflammation, suppresses osteoclastogenesis, and increases the expression of various growth factors in mesenchymal cells.
Summary and conclusions Despite some notable differences of the studies, the overall findings suggest a positive effect of PRF on cell proliferation, migration, adhesion, differentiation, and inflammation pointing towards a therapeutic potential in regenerative dentistry.
Clinical relevance PRF serves as a reservoir of bioactive molecules to support wound healing and bone regeneration. Although the cellular mechanisms by which PRF supports the clinical outcomes remain unclear, in vitro research provides possible explanations. This systematic review aims to provide an update of the existing research on how PRF affects basic physiological processes in vitro. The overall findings suggest that PRF induces cell proliferation, migration, adhesion, and differentiation along with possessing anti-inflammatory properties further supporting its therapeutic potential in wound healing and bone regeneration.

Keywords Platelet-rich fibrin · In vitro · Growth factor · Cell proliferation · Cell migration · Cell differentiation · Anti-inflammatory agents · Osteoclastogenesis

Introduction
Platelet-rich fibrin (PRF) is becoming an attractive and widely-used approach in regenerative dentistry. PRF is a platelet-rich plasma that undergoes natural coagulation after being separated from the red thrombus by centrifugation [1]. The evolution of PRF started with the introduction of L-PRF based on a high-speed protocol (~ 700 g for 12 min) [1]. Later on, A-PRF (~ 200 g for 8 min) and injectable PRF (~ 60 g for 3 min) with lower g-forces and centrifugation times were introduced with the overall aim to increase the number of platelets and leucocytes [2]. For this aim, the use of centrifuges with swing-out rotors has also been recommended [2]. Obviously PRF is an umbrella term that comprises various preparations and protocols, therefore a
standardization of relative centrifugal forces (RCF) [3] has been suggested. Nonetheless, most of the clinical data derive from the classical L-PRF protocol [1].

Recent systematic reviews dealt with the clinical application of PRF in periodontal defects, periodontal plastic surgery [4], sinus floor elevation, alveolar ridge preservation, or implant therapy [5]. For example, PRF preserves the alveolar ridge after tooth extraction [6], enhances osseointegration in the early phase [7, 8] and can increase the width of keratinized mucosa around implants [9]. Even though emerging evidence indicates that local application of PRF can support the outcomes of the above-mentioned clinical indications, the underlying cellular mechanisms remain unclear. Based on the assumption that PRF supports the conserved cellular mechanisms of wound healing and bone regeneration, it can, therefore, be assumed that PRF drives the cellular responses also under in vitro conditions.

In vitro bioassays can confirm the impact of PRF on standard cellular responses such as proliferation, migration, and differentiation, all of which may predict a possible clinical efficacy. However, care should be taken when interpreting the observations, as the early hematoma that usually forms in defect sites is not represented in the in vitro assays [10].

Readers of this review should also be aware that some of the observations reported for PRF have already been shown for plasma-free leucocyte-depleted activated platelets [11–13] based on the compelling in vitro evidence gained from platelet-rich plasma [14, 15].

The cellular responses to PRF were summarized in a systematic review integrating seven in vitro studies [16]. However, given the increasing number of in vitro studies, not limited to dentistry, a revised view on today’s in vitro research on PRF seems justified. This systematic review aims to provide an update of the existing research on how PRF affects basic physiological processes in vitro.

Material and methods

Protocol development and eligibility criteria

A protocol including all aspects of a systematic review methodology was developed prior to starting the review. This included definition of the focused question, a defined search strategy, study inclusion criteria, determination of outcome

Fig. 1 PRISMA Flow Diagram

1746 records identified through database searching

1687 records excluded

59 full-text articles assessed for eligibility

22 articles excluded

37 articles assessed for quality

37 articles included
measures, screening methods, data extraction, and analysis and data synthesis.

**Defining the focused question**

The following focused question was defined: “what is the effect of PRF on cell behavior in in vitro studies?”

**Search strategy**

An electronic search using MEDLINE database was performed. Articles published up to June 30, 2018 were considered. No language or time restrictions were applied in the search. However, only studies written in English were included for selection.

**Search terms**

The electronic search strategy included terms related to the intervention and used the following combination of key words and MeSH terms: leukocyte platelet-rich fibrin” OR “pure platelet-rich fibrin” OR “L-PRF” OR “L-PRF” OR “advanced platelet-rich fibrin” OR “APRF” OR “A-PRF” OR “L-PRF Gel” OR “leukocytes” OR “platelets” OR “blood platelets” OR “platelet” AND “in vitro techniques” OR “cytokines” OR “intercellular signaling peptides and proteins” OR “intercellular” OR intercellular signaling peptides and proteins” OR “growth factors” OR “transforming growth factor beta” OR “bone marrow” OR “stem cells” OR “macrophages” OR “osteoclasts” OR “inflammation” OR “Cell Physiological Phenomena” OR “Cell Plasticity” OR “cell differentiation” OR “osseointegration” OR “Dental Implants.”

**Criteria for study selection and inclusion**

Only in vitro studies evaluating the effect of PRF were considered.

**Exclusion criteria**

In vitro studies using other kinds of platelet concentrates such as PRGF or PRP or any other platelet concentrate that required the addition of anticoagulant. Pre-clinical and in vitro studies that did not use human blood.

**Screening and selection of studies**

Publication records and titles identified by the electronic search were independently screened by two reviewers (JN and ZK) based on the inclusion criteria. Discrepancies were solved by discussion among authors (RG and FJS). Cohen’s Kappa-coefficient was used as a measure of agreement between the readers. Thereafter, full texts of the selected abstracts were obtained. The two reviewers independently performed the screening process, i.e., from the MeSH term search up to the full-text examination. Then, articles that met the inclusion criteria were processed for data extraction.

**Data extraction and analysis**

The inclusion criteria were applied for data extraction. The studies were classified according to study design and type of methods applied. Then, outcomes were compiled in tables. All extracted data were double-checked, and any questions that came up during the screening and the data extraction were discussed within the authors to aim for consensus.

**Results**

**Selection of studies**

In the original search 1746 potential references were identified in Medline which 59 were eligible after title and abstract screening (inter-reviewer agreement $\kappa = 0.952$). Of the 59 full-text articles, 22 did not meet the inclusion criteria and were excluded (Fig. 1) obtaining 37 studies for data extraction (Table 1). During the submission-process of the present review, 16 new studies meeting the inclusion criteria were published and therefore included for data extraction (Table 2).

**Proliferation**

PRF increased proliferation of mesenchymal cells, for example from bone of different origin [19, 24–26, 28, 45, 50, 66, ], bone marrow [32, 39], periosteum [27], adipose tissue [37, 47, 68], and skin [65, 48]. Also, fibroblasts from gingiva [38, 44], periodontal ligament [18, 52, 59], papilla [30], and dental pulp responded to PRF with increased proliferation [29, 31, 43, 54]. These observations were reproduced in embryonic kidney fibroblasts and in various cell lines such as HEK293, MG-63 osteosarcoma cells, human oral keratinocytes, SIRC, and 3T3 cells [18]. Mesenchymal cells, endothelial cells [23, 42, 55, 63], epithelial cells [22], and macrophages [69] also responded to PRF with increasing proliferation. In contrast, PRF failed to induce proliferation of L929 fibroblasts [53] and human mesenchymal stem cells on collagen scaffolds [17]. In general, PRF maintained cell viability [33, 63–66, ] without inducing apoptosis [40]. Overall, there is a general consensus that PRF has a potent mitogenic activity.

**Migration**

There are various methods to identify the impact of PRF on cell migration including the scratch assay [70] and the traditional Boyden chamber approach [71]. Regardless of the
### Table 1: Included studies

| Study (year) | Cell type | PRF preparation | Method | Main outcome induced by PRF |
|--------------|-----------|-----------------|--------|----------------------------|
| Beitzel et al. (2014) [17] | Human mesenchymal stem cells (MSCs) | 3000 rpm 10 min Hardware: NR | Cell viability by live and dead staining, Cell adhesion assay to the PRF-Matrix, Cell proliferation by incorporation of 3H-thymidine | Cell viability maintained, Increased cell adhesion, No effect in cell proliferation on collagen membranes |
| Burnouf et al. (2012) [18] | Human embryonic kidney fibroblasts (HEK293), human osteoblastic cell line (MG-63), SIRC, NIH/3T3, periodontal ligament cells (PDL), gingival fibroblasts (GF) | 700 g 12 min Hardware: | Cell proliferation by an automated cell counter | Increased proliferation of all cells except for NIH/3T3 after 7 days of stimulation |
| Chang et al. (2010) [19] | Osteoblast cell line U2OS | 3000 rpm 12 min Hardware: | Cell proliferation by MTT assay Western blot for ERK phosphorylation, RANKL and OPG expression | Increased proliferation after 1, 3 and 5 days, Increased ERK phosphorylation during 5 days and OPG expression during 3 days |
| Chang et al. (2011) [20] | Periodontal ligament fibroblasts (PDLFs) | 3000 rpm 12 min Hardware: | Western blot for p-ERK and OPG ALP activity | Increased ERK phosphorylation and OPG protein expression up to 5 days, Enhanced ALP activity up to 5 days |
| Clipet et al. (2012) [21] | SaOS2 (osteoblasts), MRC5 (fibroblasts) KB (epithelial cells) | 400 g 12 min Hardware: | Cell proliferation by SRB assay Cytotoxic assay by SRB assay Cell cycle analysis by flow cytometry tests Gene expression of cbfa1, Col1, OC and OP by RT-PCR | Increased proliferation of SaOS2, MRC5 and KB, Enhanced G2M phase in SAOS2 and MRC5 lineages, Up-regulation of OP and OC on SAOS2 |
| Dereli et al. (2018) [22] | Limbal epithelial cells | PRF gel: 1000 rpm/5 min PRF: 2700 rpm/12 min Hardware: | Cell viability by live and dead staining | Cell viability maintained |
| Dohle et al. (2018) [23] | Human outgrowth endothelial cells (OECs) primary osteoblasts (pOBs) | 700 rpm 3 min Hardware: | Co-culture of OECs with pOBs Angiogenic activation by immunofluorescent staining ELISA for VEGF, PDGF-BB, E-selectin and ICAM-1 Gene expression of VEGFA, ICAM1, PDGF-BB, E-selectin, BMP2 and ALP by RT-PCR | Increased VEGF concentration on pOBs at 7 days, Increased of PDGF and E-Sel levels in OECs and pOBs co-cultures at the mRNA level and protein level at 24 and 72 h, Increased expression of ICAM1 and ALP at 24 h in OECs and pOBs co-cultures, Upregulation of VEGF expression in PRF co-culture at 1 and 7 days, Increased BMP2 expression in PRF co-cultures cultivated at 1 and 7 days |
| Ehrenfest et al. (2009) [24] | Osteoblasts, fibroblasts, preadipocytes, prekeratinocytes | 400 g 12 min Hardware: | Proliferation assay Cytotoxicity by MTT assay Osteoblast differentiation by Von Kossa and ALP staining | Increased proliferation of fibroblasts and osteoblasts at 3, 7, 14 and 21 days in a dose-dependent manner on osteoblasts, Absence of cytotoxicity in all cells, Increased ALP activity after 3 days and up to 28 days and increased osteoblasts differentiation after 7 days and up to 28 days |
| Ehrenfest et al. (2010) [25] | Human bone mesenchymal stem cells (BMSC) | 400 g 12 min Hardware: | Proliferation and cytotoxicity by MTT assay Osteoblastic differentiation by ALP activity and quantification of the mineralization nodules | Increased proliferation in standard and osteogenic conditions in a dose-dependent manner, Absence of cytotoxicity on BMSC in standard osteogenic conditions |
| Study (year) | Cell type |
|-------------|-----------|
|             | Human osteoblasts | Gassling et al. (2013) [26] |
|             | Human periosteal cells | Gassling et al. (2010) [27] |
|             | Rat calvaria osteoblasts | He et al. (2009) [28] |
|             | Human dental pulp cell (hDPC) | He et al. (2016) [29] |
|             | Human Stem Cells of the Apical Papilla (SCAPs) | Hong et al. (2018) [30] |
|             | Dental pulp cells (DPCs) | Huang et al. (2010) [31] |
|             | Human alveolar bone marrow stem cells (hABMScs) | Kang et al. (2011) [32] |
|             | Dental pulp stem cells (DPSCs) periodontal ligament stem cells (PDLSCs) | Khurana et al. (2017) [33] |
|             | Human derived osteoblasts | Kim et al. (2017) [34] |
|             | Dental pulp stem cells (HDPCs) | Kim et al. (2017) [34] |
|             | Human umbilical vein endothelial cells (HUVECs) | Kobayashi et al. (2015) [35] |

| PRF preparation | Method | Main outcome induced by PRF |
|-----------------|--------|----------------------------|
| 400 g 12 min | Cell viability by live and dead staining | Increased ALP activity in a dose-dependent manner in standard and osteogenic conditions |
| Hardware: NR 2700 rpm 10 min | Cell viability by live and dead staining | Cell viability maintained |
| | Biocompatibility and cell proliferation by LDH test and MTT assay | Increased ALP activity |
| | Cell Proliferation by BrdU | Enhanced migration at 1, 3, and 5 days |
| | Cell viability by trypan blue | Absence of cytotoxicity at 7 days |
| | Cell viability by live and dead staining | Increased ALP activity |
| 400 g 10 min | Cell Proliferation | Increased proliferation at 5 days and enhanced mineralization at 14 days |
| Hardware: NR | Mineralization assay by alizarin red staining | No effect on ALP activity |
| 400 g 10 min | Cell Proliferation | Increased proliferation after 5 and 7 days |
| Hardware: NR | Proliferation assay by CCK-8 | Up-regulation of ALP and DSPP expression |
| 400 g 10 min | Cell migration assay | Increased proliferation at 1, 3, and 5 days |
| Hardware: NR | Osteogenic differentiation by alizarin red staining | Enhanced migration at 12 and 24 h |
| 400 g 10 min | Cell viability by trypan blue | Increased migration at 1 and 2 days |
| Hardware: NR | Cell viability by live and dead staining | Enhanced mineralization |
| 3000 rpm 10 min | Cell proliferation | Increased proliferation at 1, 2, and 3 days |
| Hardware: c | Osteoblast differentiation by ALP activity assay | Increased ALP activity at 2 and 3 days |
| 400 g 10 min | Cell viability by MTT assay | Absence of cytotoxicity |
| Hardware: d | Osteoblast differentiation by Sulforhodamine B assay | Reduced LPS-induced pro-inflammatory cytokines IL-1β, IL-6, and IL-8 at 1 and 3 days |
| 600 g/2 min + 500 g/4 min + 800 g/3 min | Cell viability by MTT assay ELISA for IL-1β, IL-6, and IL-8 | Enhanced LPS-induced expression of osteoblastic differentiation markers DSP and DMP1 at 3 days |
| Scratch assay | Western blot for VEGFR2 | Increased ALP activity and mineralization at day 7 in LPS treated cells |
| 400 g 10 min | Cell viability by MTT assay | Absence of cytotoxicity |
| Hardware: NR | Osteoblast differentiation by ALP activity | Reduced LPS-induced pro-inflammatory cytokines IL-1β, IL-6, and IL-8 at 1 and 3 days |
| 400 g 10 min | Cell viability by MTT assay | Enhanced LPS-induced up-regulation of osteoblastic differentiation markers DSP and DMP1 at 3 days |
| Hardware: NR | Osteoblast differentiation by ALP activity | Enhanced LPS-induced up-regulation of osteoblastic differentiation markers DSP and DMP1 at 3 days |
| 400 g 10 min | Cell viability by MTT assay | Increased ALP activity and mineralization at day 7 in LPS treated cells |
| Hardware: e | Osteoblast differentiation by ALP activity | Increased number of blood capillaries |
| Study (year)                | Cell type                  | PRF preparation     | Method                                                                 | Main outcome induced by PRF                                                                 |
|---------------------------|----------------------------|---------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Fujioka-Kobayashi et al. 2017 [36] | Human gingival fibroblasts | Hardware: Hardware: | Cell viability by live-dead staining, Cell migration assay              | Cell viability maintained, Increased migration, Increased proliferation at 3 and 5 days, Up-regulation of PDGF and COL1a2 expression and TGFβ and COL1a2 at day 7 |
| Liang et al. 2018 [37]     | Nanofat-derived stem cells (NFSCs) | Hardware: 2700 rpm | Cell proliferation by CCK-8                                            | Increased proliferation, Increased expression and protein levels of VEGF, bFGF, PDGF and TGFβ, Enhanced osteogenic, adipogenic and chondrogenic differentiation |
| Miron et al. 2017 [38]     | Human gingival fibroblasts (HGF) | Hardware: L-PRF: 700 rpm | Cell viability by live and dead assay, Cell migration by Boyden chamber, Cell proliferation by MTS assay | Increased cell migration, Increased proliferation after 5 days, Up-regulation of COL1a2 and PDGF expression after 3 days, and TGFβ and COL1a2 after 7 days |
| Moradian et al. 2017 [39]  | Human bone marrow mesenchymal stem cells (BMMSCs) | Hardware: 400 g 10 min | Cell proliferation by MTT assay                                        | Increased proliferation at 7 days                                                                 |
| Schär et al. 2015 [40]     | Human bone marrow-derived MSC and HUVEC | Hardware: 400 g 12 min | Cell migration assay by Boyden chambers                                | Increased migration of MSC and HUVEC cells at 7 days and at 8 h, respectively                |
| Park et al. 2018 [41]      | Human umbilical vein endothelial cell (HUVEC) | Hardware: 400 g 12 min | Cell proliferation by MTT assay                                        | Increased proliferation, migration and attachment of cells by coating porcine-matrices with PRF |
| Passaretti et al. 2014 [42]| HUVEC, skin fibroblasts     | Hardware: 400 g 12 min | Cell attachment by Green Nucleic Stain-Kit                             | Increased cell proliferation at 24 h                                                         |
| Saeed et al. 2017 [43]     | Dental pulp stem cells (DPSCs) | Hardware: 2700 rpm | Cell proliferation by MTS assay, Osteogenic differentiation by alizarin red assay | Reduced cell viability at 1 and 3 days by most PRF concentrations, Enhanced osteogenic differentiation at 7 days |
| Vahabi et al. 2015 [44]    | Human gingival fibroblasts cell line (HGF) | Hardware: 400 g 12 min | Viability and proliferation by MTT assay                               | Cell viability maintained during the first 24 h, at 48 and 72 h cell viability is reduced, Increased proliferation only the first 24 h |
| Wang et al. 2018 [45]      | Human primary osteoblasts   | Hardware: L-PRF: 700 rpm | Cell viability by live and dead staining, Cell migration by polyethylene terephthalate cell culture inserts | Cell viability maintained, Increased migration at 1 day, No effect on cell adhesion, Increased proliferation at 3 and 5 days, Enhanced ALP activity and mineralized nodule formation, Up-regulation of ALP expression at 3 days and OCN, Runx2 and COL1A at 14 days, Increased staining intensity of OCN |
| Wang et al. 2017 [46]      | Human gingival fibroblasts  | Hardware: 700 rpm 60 g 3 min | Cell viability by live-dead staining, Cell migration by polyethylene terephthalate cell culture inserts, Cell adhesion assay | Cell viability maintained irrespective of the titanium surface, Increased migration in tissue culture plates and titanium surfaces, No effect on cell adhesion |
| Study (year) | Cell type | PRF preparation | Method | Main outcome induced by PRF |
|-------------|-----------|-----------------|--------|-----------------------------|
| Wei et al. (2017) [47] | Nanofat-derived Stem Cells (NFSCs) | 2700 rpm 12 min | Proliferation assay by CCK-8 Gene expression of PDGF, TGF-β and COL1a1 and FN1 Collagen Type I Staining Immunostaining | Increased cell proliferation after 3 and 5 days Upregulation of PDGF, TGF-β, COL1 and FN1 expression levels on all surfaces Increased fluorescence intensity of collagen type 1 on all surfaces. |
| Wirohadidjojo et al. (2016) [48] | Ultraviolet-A (UVA)-irradiated human dermal fibroblasts (HDFs) | 400 g 12 min | Proliferation assay by MTT assay Collagen deposition assay Cell migration rate assay | Increased proliferation after 3 days Enhanced adipogenic differentiation at 14 days in a dose dependent-manner Up-regulation of PPARγ2, C/EBPα, and ADD1 expression |
| Woo et al. (2016) [49] | Human dental pulp cells (HDPCs) | 400 g 10 min | Cell viability by MTT and MTA assay ALP activity assay ALP staining Alizarin red staining for mineralization formation Western Blot for DSP, DMP1, BMP 2/4, phospho-smad1/5/8 | Cell viability maintained at 48 h Increased protein levels of DSP and DMP1 and enhanced ALP activity. Increased mineralization Activation of BMP 2/4 signaling and phosphorylation of SMAD1/5/8 |
| Wu et al. (2012) [50] | Human osteoblast cell line (U2OS) | 3000 rpm 12 min | Cell attachment assay by WST-1 assay Cell proliferation assay Western blot analysis for p-Akt, HSP 47 and LOX | Increased cell attachment the first 3 h Increased proliferation at 1, 3 and 5 days. Enhanced Akt phosphorylation, HSP 47 expression, and LOX expression in U2OS cells |
| Xu et al. (2016) [51] | Human breast adipose-derived stem cells (HBASCs) | 2700 rpm 12 min | Attachment of HBASCs on scaffolds in the presence of PRF, Rg1 or both by fluorescence imaging | Increased proliferation and attachment on scaffolds |
| Zhao et al. (2013) [52] | Periodontal ligament stem cells (PDLSCs) | 400 g 10 min | Cell viability and proliferation assay by MTT assay ALP activity Gene expression of BSP, OCN, Coll, and CP23 by RT-PCR | Cell viability maintained Increased proliferation during 7 days Reduced ALP activity at 7 days Down-regulation of BSP and OCN expression at 7, 14 and 21 days Up-regulation PDL-related genes Coll and CP23 |

Note: NR not reported, MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide, ERK extracellular signal-regulated kinase, RANKL receptor activator of NF-κB ligand, OPG osteoprotegerin, ALP alkaline phosphatase, SRR sulforhodamine B, cbfa1 core-binding factor subunit alpha-1, LPS lipopolysaccharide, VEGF vascular endothelial growth factor, ICAM-1 intercellular adhesion molecule 1, ELISA enzyme-linked immunosorbent assay, BMP bone morphogenetic protein, RT-PCR reverse transcription polymerase chain reaction, BrdU bromodeoxyuridine, WST-1 water soluble tetrazolium-1, LDH lactate dehydrogenase, CCK-8 cell counting kit-8, BSP bone sialoprotein, DMP dentin matrix protein, MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, TGF-β transforming growth factor-β, COL1a2 collagen type 1 alpha 2, bFGF basic fibroblast growth factor, Runx2 runt-related transcription factor 2, OCN osteocalcin, FN1 fibronectin, ECM extracellular matrix, PPARγ2 peroxisome proliferator-activated receptor, CEBPβ CCAAT-enhancer-binding proteins

a PC-02, Nice, France
b Hettich EBA20, Tuttlingen, Germany
c Duo Centrifuge, Nice, France
d Eppendorf Centrifuge 5702, Hamburg, Germany
e Gyrozen 406, Daejeon, Korea
f Medifuge centrifugation system, Santa Sofia, Italy
method used, PRF increased the migration of neural stem cells [54] along with cells of the mesenchymal lineage isolated from bone [45, 64], bone marrow [72], gingiva [38, 64, 36], apical papilla [30], and skin [65, 48]. Similarly, endothelial cells responded to PRF with an increased migration [63, 72, 41]. In contrast, an inhibitory effect of PRF on cell migration was also observed on bone marrow cells but likely due to the aggregation and proliferation effect of PRF that precedes migration [32]. Likewise, in one recent study, PRF failed to induce migration on L929 fibroblasts [53]. However, the general view is that PRF supports cell motility.

**Alkaline phosphatase and alizarin red staining**

The main early marker of osteogenic differentiation is alkaline phosphatase [73]. Various studies showed that PRF increases the expression or the activity of alkaline phosphatase in cells of the mesenchymal lineage isolated from bone [45, ], bone marrow [25], apical papilla [30], dental pulp [31, 34, 43, 49], periodontal ligament [59, 74], osteosarcoma cell lines [21], and other tissues [24]. Moreover, PRF increased mineralized nodules in cells from dental pulp [34, 43, 49], calvaria bone [28], bone marrow [32], and periodontal ligament [59]. Conversely, one study showed an inhibitory effect of PRF on alkaline phosphatase activity [52]. In two other reports, PRF failed to change alkaline phosphatase activity and did not change alkaline phosphatase expression in rat calvaria osteoblasts [28] and bone marrow cells [40], respectively. Taken together, all but three studies reported an increase of alkaline phosphatase in response to PRF exposure.

**Growth factors and extracellular matrix**

PRF caused a moderate expression of various growth factors in mesenchymal and endothelial cells such as TGFβ [38, 46, 52, 56, 65, 36], PDGF [23, 38, 40, 46, 52, 56, 65, 36], and VEGF [23, 37, 58]. Dental pulp cells treated with PRF increased expression of dentin sialoprotein and dentin matrix protein 1 [29, 34, 49]. With respect to changes in the expression of extracellular matrix protein, PRF increased collagen type 1 in mesenchymal cells of the bone [45], skin [65], and gingiva [38, 73]. Likewise, PRF increased the expression of osteopontin, MMP2, and MMP9 in human bone marrow cells [40]. Conversely, PRF reduced the expression of bone sialoprotein and osteocalcin along with a transient downregulation of collagen type 1 in periodontal ligament cells [52]. Similarly, a downregulation of bone sialoprotein, dentin matrix protein 1, and dentin sialoprotein in cells from the papilla was reported [30]. It should be noted, however, that this downregulation disappeared after 14 days of stimulation [30]. In general, the reported increase of gene expression by PRF is moderate.

**Cell adhesion**

Cell adhesion proteins were enhanced by PRF, for example, ICAM-1 and E-selectin in cocultures of osteogenic and endothelial cells [23] and ICAM-1 in pulp cells [34]. Furthermore, PRF supported adhesion of mesenchymal cells [17], HUVEC [41], U2OS [50], and HBASC [51] on different scaffolds. These positive results nonetheless were not replicated on titanium surfaces [46] and culture plates [45]. Together, these observations suggest that in the majority of experiments, PRF could support cell adhesion.

**Cell signaling, inflammation, and osteoclastogenesis**

PRF enhanced the phosphorylation of Akt, heat shock protein 47 and lysis oxidase in osteosarcoma cells [50], and VEGFR2 in endothelial cells [35]. PRF enhanced phosphorylation of ERK in osteosarcoma cells [19], and periodontal fibroblasts [74] along with an increase in OPG expression in both cell types. This PRF-induced OPG expression was also reported on dental pulp cells [31]. Moreover, PRF reduced LPS-induced cytokine production in pulp cells and enhanced the up-regulation of odontoblastic differentiation markers DSP and DMP-1 in these cells [34]. Similarly, PRF suppressed the LPS- and saliva-induced pro-inflammatory cytokines on primary and RAW264.7 macrophages and attenuated the translocation of NF-κB into the nucleus [69]. This anti-inflammatory effect was replicated in gingival fibroblasts [61]. In addition, in dental pulp cells, PRF increased DSP and DMP1 expression along with an activation of BMP 2/4 signaling and phosphorylation of SMAD1/5/8 cascade [49]. Osteoclasts originate from hematopoietic progenitors and in the presence of the survival factor (M-CSF) and RANKL differentiate into osteoclasts staining positive for TRAP. PRF suppressed the expression of osteoclast marker genes TRAP, DCSTAMP, NFATc, and OSCAR. Altogether, these results suggest that PRF can affect central signaling pathways, possesses an anti-inflammatory effect, and is capable of inhibiting osteoclastogenesis [57].

**Discussion**

This systematic review encompassed in vitro studies using PRF and can be viewed as an extension of the previous work of Miron et al. [16]. Our aim was to gather the current in vitro evidence on cellular responses to PRF.
| Study (year)         | Cell type                                              | PRF preparation | Method                                      | Main outcome induced by PRF                                             |
|---------------------|--------------------------------------------------------|-----------------|---------------------------------------------|------------------------------------------------------------------------|
| Bucur et al. (2019) | Fibroblast cell line L929                            | 200 g           | Cell proliferation and migration using RCTA  | No effect on proliferation neither on migration                         |
|                     |                                                       | 14 min          | Scratch assay                               |                                                                        |
|                     |                                                       | Hardware: NR    |                                             |                                                                        |
| Elgamal et al. (2019)| Adipose mesenchymal stem cells (MSC)                  | 1500 rpm        | Cell proliferation by MTT assay             | Increased proliferation                                               |
|                     |                                                       | 14 min          |                                             |                                                                        |
|                     |                                                       | Hardware: NR    |                                             |                                                                        |
| Gervois et al. (2019)| Human dental pulp stem cells (hDPSCs), neural stem cell (NSC) | 400 g           | Metabolic activity assay by MTT assay       | Decreased and increased metabolic activity, dependent on the PRF concentration |
|                     |                                                       | 12 min          | Cell proliferation by PI assay              | Increased proliferation of hDPSCs but no effect on NSC                 |
|                     |                                                       | Hardware: c     | Cell migration by transwell migration assay  | Increased migration of NSC                                            |
| Gomez et al. (2019) | Endothelial cells (EC)                                | 2000 rpm        | Counting of the cells viewed under phase-contrast microscope | Increased cell growth                                                 |
|                     |                                                       | 7 min           |                                             |                                                                        |
|                     |                                                       | Hardware: NR    |                                             |                                                                        |
| Herrera-Vizcaíno et al. (2019) | Human dermal vascular endothelial cells (HDMECs) | 44 g or 710 g   | Immunostaining of endothelial cells marker CD31 | Increased CD31-positive cells                                          |
|                     |                                                       | 8 min           | Immunohistochemical detection of CD31       | Increased concentration of PDGF-BB of TGFβ at day 4 in HDMECs and HF  |
|                     |                                                       | Hardware: a     | Protein levels of VEGF, PDGF-BB and TGFβ by ELISA | No effect on VEGF                                                   |
| Kargarpour et al. (2019) | Murine primary macrophages, RAW264.7 cells | 1570 rpm        | Cell viability by MTT assay and live-dead staining | Maintenance of cell viability and enhanced cell proliferation         |
|                     |                                                       | 12 min          | Cell proliferation by BrdU                  | Reduced caspase 3 activity and suppression of cleaved caspase-3     |
|                     |                                                       | Hardware: d     | Caspase 3 activity assay                    | Suppression of osteoclastogenesis                                     |
|                     |                                                       |                 | Western blot for cleaved caspase 3          | Suppression of the expression of TRAP, Cathepsin K, DCSTAMP, NFATc1, OSCAR, and pro and anti-apoptotic marker genes, caspase-3, Bax and Bcl2L1 by RT-PCR |
|                     |                                                       |                 | Gene expression of oestroblast marker genes TRAP, Cathepsin K, DCSTAMP, NFATc1, OSCAR and pro and anti-apoptotic marker genes, caspase-3, Bax and Bcl2L1 by RT-PCR |
|                     |                                                       |                 | TRAP staining                               | Reduced number of multinucleated TRAP positive cells                  |
|                     |                                                       |                 | Pit formation assay                         | Reduced pit formation on dentine slices                               |
| Kasnak et al. (2019) | Human oral keratinocyte (HMK) cells                  | 2700 rpm        | Cell proliferation by CellTiter 96 assay    | Increased proliferation on titanium and hydroxyapatite discs           |
|                     |                                                       | 15 min          | Protein levels of IL1β, IL1Ra, IL8, MCP1, and VEGF by ELISA | Increased concentration of IL1β, IL1Ra, IL8, MCP1, and VEGF on titanium and hydroxyapatite discs |
|                     |                                                       | Hardware: e     |                                             |                                                                        |
| Li et al. (2018)    | Human periodontal ligament cells (hPDLCs)            | 750 g           | Cell proliferation using CCK-8 ALP assay activity | Increased proliferation at day 1, 2 and 3                             |
|                     |                                                       | 12 min          | Mineralization assay by alizarin red staining | Increased ALP activity at 7 and 14 days                               |
|                     |                                                       | 5 min           | Gene expression of RUNX2, Osterix and Osteocalcin by RT-PCR | Increased mineralization at 14 days                                   |
|                     |                                                       | Hardware: NR    | Protein expression of RUNX2 by Western blot | Increased expression of RUNX2, Osterix at 5 and 7 days and Osteocalcin at 7 days |
| Mahendran et al. (2019) | Fibroblast cell line L929                            | 3000 rpm        | Cell viability by MTT assay                | Increased protein expression of RUNX2 at day 5                         |
|                     |                                                       | 10 min          |                                             | Maintenance of cell viability                                         |
|                     |                                                       | Hardware: NR    |                                             |                                                                        |
| Muralal et al. (2019) | Human gingival fibroblast                            | 3000 rpm        | Gene expression of IL1β, IL6 and TNFα by RT-PCR | Decreased expression of IL1β, IL6 and TNFα                           |
|                     |                                                       | 12 min          |                                             |                                                                        |
| Nasirzade et al. (2019) | Murine primary macrophages, Raw 264.7 cells | 1570 rpm        | Gene expression of M1 marker genes IL1β, IL6; M2 genes Arg1, Ym1 and lipoxigenases, ALOX12, and ALOX15 by RT-PCR | Decreased expression of IL1β and IL6 Increased expression of Arg1, Ym1 and lipoxigenases Increased IL6 protein level Reduced intracellular translocation of NF- B |
|                     |                                                       | 12 min          | IL6 levels by ELISA                         |                                                                        |
|                     |                                                       | Hardware: d     | NF- B intracellular translocation by Immunofluorescent |                                                                        |
Despite the steadily increasing number of in vitro studies, much of the available evidence has focused on confirming similar findings. The majority of studies assessed the impact of PRF on proliferation, adhesion, migration, and differentiation mainly on mesenchymal cells and to some extent, endothelial and epithelial cells. Overall, PRF triggered an increase in the above-mentioned parameters and revealed anti-inflammatory properties. PRF also showed a moderate but consistent capacity to modulate the expression of target genes activating different signaling pathways.

A meta-analysis could not be performed as the included studies revealed heterogeneity in terms of study design, evaluation methods, outcome measures, and observation periods. Besides the original L-PRF protocol, other PRF protocols were used, however, most studies did not provide enough details. These details are of importance as with different protocols [3], i.e., centrifugation time and g-force, characteristics such as the release of growth factors or the content of living cells are substantially changed [75]. For instance, by reducing such as the release of growth factors or the content of living cells are substantially changed [75]. For instance, by reducing

### Table 2 (continued)

| Study (year) | Cell type | PRF preparation | Method | Main outcome induced by PRF |
|--------------|-----------|----------------|--------|-----------------------------|
| Ratajczak et al. (2018) [63] | HUVEC | 400 g 12 min | Cell proliferation by MTT assay and propidium iodide assay | Increased proliferation |
| Steller et al. (2019) [64] | Primary human osteoblasts (OB) | 400 g 10 min | Viability by MTT assay | Increased migration |
| Steller et al. (2019) [64] | Human gingival fibroblasts (GF), human osteoblasts (hOB) | 400 g 10 min | Cell viability by MTT assay | Increased tube formation |
| Verboket et al. (2019) [40] | Bone marrow mononuclear cells (BMC) | 60 g 3 min | Metabolic activity by MTS assay | Increased tube formation |
| Wang et al. (2019) [65] | Dermal skin fibroblast cell | 60 g 3 min | Cell viability using live and dead staining | Increased tube formation |

**Note.** NR not reported, MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide, ALP alkaline phosphatase, COL1A1 collagen 1 alpha 1, RT-PCR reverse transcription polymerase chain reaction, ELISA enzyme-linked immunosorbent assay, VEGF vascular endothelial growth factor, ICAM1 intercellular adhesion molecule, SPPI osteopontin, PDGF-BB platelet-derived growth factor, PI propidium iodide, BDNF brain-derived neurotrophic factor, CCK-8 cell counting kit-8, TGF-β transforming growth factor-β, TRAP tartrate-resistant acid phosphatase, DCSTAMP dendritic cell-specific transmembrane protein, NFATc1 nuclear factor of activated T-cells, OSCAR osteoclast-associated receptor, Bax Bcl2-associated x protein, Bcl2 B cell lymphoma 2, MCP-1 monocyte chemotactic protein-1, MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, FGF23 basic fibroblast growth factor, TNF-α tumor necrosis factor, Arg1 arginase-1, ALOX arachidonate lypoxigenase, NF nuclear factor kappa-light-chain-enhancer of activated B cells, RTCA real-time-cell analyzer assay, M-CSF macrophage colony stimulating factor, MMP matrix metalloproteinase, FN1 fibronectin

![Springer](https://example.com/springer-logo.png)
preparation protocols such as the centrifugation tubes which have a strong impact on the clot size [76]. Indeed, the silica used to coat plastic tubes might contaminate PRF and thereby provoking inflammation [77]. Likewise, differences in g-forces, blood volume, hematocrit levels, centrifugation time, and handling of PRF membranes impede an accurate comparison between the protocols. Furthermore, PRF lysates, PRF conditioned medium, and PRF exudates should also be distinguished from traditional protocols. Although these issues are at the heart of scientific discussion [78, 79], the main in vitro findings are rather consistent.

Successful tissue regeneration and osseointegration rely on the response of the surrounding cells. These biological processes inevitably require proliferation, migration, and differentiation of cells at the treatment site.

PRF consistently increased cell proliferation irrespective of the cell type and PRF preparation. One interesting setting was the increased cell proliferation on collagen matrices [72] and titanium surfaces [46] upon PRF coating. It is worth noting that two studies found a conspicuously reduced proliferation in gingival fibroblast [44] and dental pulp stem cells [43]. It is difficult, however, to determine why PRF led to a decline in cell proliferation. PRF membranes covering cells might decrease oxygenation [44]. Nonetheless, PRF preparation without providing enough details complicates the interpretation of the data [43]. Despite these shortcomings, the majority of the in vitro studies suggest a mitogenic activity of PRF for various cell types that might be attributed to the strong mitogen PDGF released by activated platelets [13, 80].

Cell migration was positively induced in all but two of the selected studies. This chemotactic effect is likely due to the presence of growth factors contained in platelets such as PDGF [12]. This growth factor, for example, pushes proliferation of osteogenic cells in vitro [81]. In addition, endothelial cells followed a similar pattern of displaying an increase in migration upon exposure to PRF [40]. Although the activation of platelets might account for these observations [11], the precise mechanism remains to be elucidated. In support of the mitogenic and chemotactic activity, PRF enhanced the phosphorylation of Akt [50], and ERK [19, 74] similar to what is observed in isolated platelets [12]. Conversely, inhibition of migration by PRF has been reported in alveolar bone marrow cells [32]. This effect might be explained by the aggregation and proliferation effect of PRF that precedes migration and also by methodological differences, which precludes an interpretation and a comparison with the other studies [3]. Despite these inconsistencies, PRF is able to induce cell migration, likely due to the presence of growth factors such as PDGF with chemotactic activity.

Cell differentiation is commonly assessed by means of measuring alkaline phosphatase and alizarin red staining. Various studies showed that PRF increases the expression or the activity of alkaline phosphatase in cells of the mesenchymal lineage [24, 25, 29–31, 34, 43, 45, 49, 65, 59, 74]. Some data, nonetheless, are conflicting since PRF can also reduce alkaline phosphatase activity [52] consistent with the effects of supernatants of isolated platelets [12]. This reduction may be attributed to TGF-β [82] and PDGF [12]. On the other hand, the increased mineralized nodules elicited by PRF in cells from dental pulp [34, 43, 49], calvaria bone [28], bone marrow [32], and periodontal ligament [59] appear to be a consequence of the enhanced proliferation, alkaline phosphatase activity, and production of collagen matrix. These in vitro findings, however, have to be interpreted with caution as proliferation and differentiation do not occur simultaneously [73].

With respect to growth factors such as TGFβ, PDGF, and VEGF, PRF moderately increased their expression. Regarding extracellular matrix proteins, PRF moderately increased the expression of collagen type 1, which is a known TGFβ target gene [83, 84] in mesenchymal cells of various origins. In line with collagen type 1 synthesis, PRF activates the expression of HSP47 and lysine oxidase [50]. Cell adhesion proteins were enhanced by PRF [23], however, they are not necessarily responsible for the increased cell adhesion on different scaffolds [51]. Together, these observations suggest that PRF induces moderate changes in gene expression. In contrast, recent data at our lab indicate a robust activation of TGFβ target genes IL11, PRG4, and NOX4 by PRF lysates (Di Summa et al. unpublished observation). TGF-β couples osteogenesis with angiogenesis by providing a pro-osteogenic microenvironment in vivo [62]. As TGF-β induces pro-osteogenic factors and TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in vivo [62], PRF-derived TGF-β may support bone regeneration.

This systematic review revealed an anti-inflammatory effect of PRF. Moreover, during the submission process of the present review, new studies were published highlighting these anti-inflammatory effects of PRF. For example, PRF reduced the LPS-induced proinflammatory cytokine release in gingival fibroblasts [61]. In addition, we have recently shown that PRF reduces the expression of the M1 marker genes interleukin 1β (IL1β) and interleukin 6 (IL6) in bone marrow macrophages [69]. This anti-inflammatory effect might be explained by the high amounts of TGFβ in PRF [73] capable of modulating the M1 and M2 polarization along with the generation of pro-resolving lipid mediators [69]. Additionally, PRF induces the expression of the M2 markers arginase-1 and chitinase-like 3 (Chil3 or YM1) thereby assisting a M1-to-M2 transition [69]. Since dental implants activate the immune system during the early stages of osseointegration [85], the addition of PRF may support a M2 polarization reducing the time lag for osseointegration and bone regeneration. Notably, PRF can also decrease the formation of osteoclast-like cell in a murine bone marrow culture [57]. Similar findings were also reported in peripheral blood mononuclear cells derived CD14+ cells.
These observations are of particular interest since the favorable effects of PRF in alveolar ridge preservation might be partly explained by an inhibition of osteoclastogenesis. Thus, accumulating evidence suggest that PRF possesses anti-inflammatory activity and is capable of suppressing osteoclastogenesis.

PRF is a potent inducer of the in vitro angiogenic process indicated by endothelial proliferation, migration, and tube formation. PRF supports microvessel-like structures and induces blood vessel formation in the chorioallantoic membrane assay. Apart from in vitro angiogenesis, a recent report described an antimicrobial effect of PRF. In that study, both PRF membranes and PRF exudates had an antimicrobial effect against P. gingivalis, a key periodontal pathogen. Those findings support the rationale of using PRF as an adjunctive therapy for peri-implantitis. These observations are also in line with previous data on purified activated platelet showing an angiogenic and antimicrobial effect. Overall, these findings imply that PRF possesses angiogenic and antimicrobial properties.

We recognize that the present report has a number of limitations. PRF is widely used in regenerative dentistry, however, in vitro models represent only a narrow aspect of wound healing and bone regeneration neglecting the holistic nature of an in vivo model. Furthermore, and considering that wound healing and bone regeneration involve granulocytes, lymphocytes and other cell types, today’s PRF research only covers a restricted spectrum of cells. It should also be noted that the same stimuli may play different roles depending on the differentiation stage of the target cell. For example, our group demonstrated that PRF membranes inhibit the formation of osteoclasts in bone marrow cultures. This inhibition, however, did not occur when osteoclastogenesis had already started.

Future studies should, for example, include research on the immigration and activation of granulocytes and how PRF might control the resolution of inflammation. Moreover, and considering the importance of centrifugation tubes and the possible impact of silica coating, more studies investigating this issue are needed for the optimization of PRF. Finally, the overall question of whether the in vitro PRF research reflects the clinical reality serving as a surrogate parameter to adapt the current PRF protocols remains to be clarified.

**Conclusion**

Despite some notable differences of the included studies, the overall findings suggest a benefit of PRF on cell proliferation, migration, adhesion, differentiation, and inflammation pointing towards a therapeutic potential in wound healing and regeneration.

**Author contributions** F.J.S. and R.G. contributed to conception and design; contributed to the literature research, analysis, and interpretation; drafted manuscript; critically revised manuscript; gave final approval; agreed to be accountable for all aspects of work. J.N. and Z.K. literature research, analysis, and interpretation; critically revised manuscript; gave final approval; agreed to be accountable for all aspects of work. A.S. analysis, and interpretation; critically revised manuscript; gave final approval; agreed to be accountable for all aspects of work.

**Funding information** Open access funding provided by Austrian Science Fund (FWF). This study was funded by a grant (17-125) from the Osteology Foundation, Switzerland. This research was further supported by a grant from Austrian Science Fund (FWF) (4072-B28). Franz Josef Strauss is supported by the Osteology Foundation and the Comisión Nacional de Investigación Científica y Tecnológica (CONICYT), Chile. Jila Nasirzade and Zahra Kargarpour received support from the Osteology Foundation. Alexandra Stähli received grants from the Swiss Dental Association (288-15), the Swiss Society of Periodontology (SSP), the Foundation for the Promotion of Oral Health and Research as well as the Osteology Foundation.

**Compliance with ethical standards**

**Conflict of interest** All authors declare that they have no conflict of interest.

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** For this type of study, formal consent is not required.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101(3):e37–e44. https://doi.org/10.1016/j.tripleo.2005.07.008
2. Miron RJ, Chai J, Zheng S, Feng M, Scaleen A, Zhang Y (2019) A novel method for evaluating and quantifying cell types in platelet rich fibrin and an introduction to horizontal centrifugation. J Biomed Mater Res A 107(10):2257–2271. https://doi.org/10.1002/jbm.a.36734
3. Miron RJ, Pinto NR, Quirynen M, Ghanaati S (2019) Standardization of relative centrifugal forces in studies related to platelet-rich fibrin. J Periodontol. https://doi.org/10.1002/JPER.18-0553
2. Castro AB, Meschi N, Temmerman A, Pinto N, Lambrechts P, Teughels W, Quirynen M (2017) Regenerative potential of leucocyte- and platelet-rich fibrin. Part A: intra-bony defects, furcation defects and periodontal plastic surgery. A systematic review and meta-analysis. J Clin Periodontol 44(1):67–82. https://doi.org/10.1111/jcpe.12643

5. Strauss FJ, Stahli A, Gruber R (2018) The use of platelet-rich fibrin to enhance the outcomes of implant therapy: a systematic review. Clin Oral Implants Res 29(Suppl 18):6–19. https://doi.org/10.1111/cir.13275

7. Öncü E, Alaaddinoglu EE (2015) The effect of platelet-rich fibrin on implant stability. The International Journal of Oral & Maxillofacial Implants 30(3):578–582. https://doi.org/10.11607/jomi.3897

8. Tabrizi R, Arabion H, Karagah T (2017) Does platelet-rich fibrin increase the stability of implants in the posterior of the maxilla? A split-mouth randomized clinical trial. Int J Oral Maxillofac Surg. https://doi.org/10.1016/j.ijoms.2017.07.025

9. Temmerman A, Cleeren GJ, Castro AB, Teughels W, Quirynen M (2018) L-PRF for increasing the width of keratized mucosa around implants: a split-mouth, randomized, controlled pilot clinical trial. J Periodontal Res 53(5):793–800. https://doi.org/10.1111/jre.12568

10. Kolar P, Schmidt-Bleek K, Schell H, Gaber T, Tohen D, Schmidmaier G, Perka C, Buttgereit F, Duda GN (2010) The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 16(4):427–434. https://doi.org/10.1089/ten.TEB.2009.0687

11. Kandler B, Fischer MB, Watzek G, Gruber R (2004) Platelet-released supernatant increases matrix metalloproteinase-2 production, migration, proliferation, and tube formation of human umbilical vascular endothelial cells. J Periodontol 75(9):1255–1261. https://doi.org/10.1902/jop.2004.75.9.1255

12. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G (2004) Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets 15(1):29–35. https://doi.org/10.1080/09537103100101643999

13. Gruber R, Varga F, Fischer MB, Watzek G (2002) Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res 13(5):529–535

14. Alsubousi J, Thompson M, Hulley P, Noble A, Willett K (2009) The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg (Br) 91(8):987–996. https://doi.org/10.1302/0301-620X.91B8.22546

15. Nikolaidakis D, Jansen JA (2008) The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B Rev 14(3):249–258. https://doi.org/10.1089/ten.teb.2008.0062

16. Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J (2017) Platelet-rich fibrin and soft tissue wound healing: a systematic review. Tissue Eng Part B Rev 23(1):83–99. https://doi.org/10.1089/ten.TEB.2016.0233

17. Beitzel K, McCarthy MB, Cote MP, Russell RP, Apostolakos J, Ramos DM, Kumbar SG, Imhoff AB, Arciero RA, Mazzaocca AD (2014) Properties of biologic scaffolds and their response to mesenchymal stem cells. Arthroscopy 30(3):289–298. https://doi.org/10.1016/j.arthro.2013.11.020

18. Burnouf T, Lee CY, Luo CW, Kuo YP, Chou ML, Wu YW, Tseng YH, Su CY (2012) Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. Biologics 40(1):21–30. https://doi.org/10.1016/j.biologics.2011.09.017

19. Chang IC, Tsai CH, Chang YC (2010) Platelet-rich fibrin modulates the expression of extracellular signal-regulated protein kinase and osteoprotegerin in human osteoblasts. J Biomed Mater Res A 95(1):327–332. https://doi.org/10.1002/jbm.a.32839

20. Chang YC, Zhao JH (2011) Effects of platelet-rich fibrin on human periodontal ligament fibroblasts and application for periodontal inflammatory defects. Australian dental journal 56 (4):365-371. https://doi.org/10.1111/j.1384-7819.2011.01362.x

21. Clipet F, Tricot S, Alno N, Massot M, Solhi H, Cathelineau G, Perez F, De Mello G, Pellen-Mussi P (2012) In vitro effects of Choukroun's platelet-rich fibrin conditioned medium on 3 different cell lines implicated in dental implantology. Implant Dent 21(1):51–56. https://doi.org/10.1097/ID.0b013e31822b9eb4

22. Dereli Can G, Akdere OE, Can ME, Aydin B, Cagil N, Gumsudereligioglu M (2018) A completely human-derived biomaterial mimicking limbal niche: platelet-rich fibrin gel. Exp Eye Res 173:1–12. https://doi.org/10.1016/j.exer.2018.04.013

23. Dohle E, El Bagdadi K, Sader R, Choukroun J, James Kirkpatrick C, Ghanati S (2018) Platelet-rich fibrin-based matrices to improve angiogenesis in an in vitro co-culture model for bone tissue engineering. J Tissue Eng Regen Med 12(3):598–610. https://doi.org/10.1002.term.2475

24. Dohan Ehrenfest DM, Diss A, Odin G, Doglioli P, Hippolyte MP, Charrier JB (2009) In vitro effects of Choukroun’s PRF (platelet-rich fibrin) on human gingival fibroblasts, dental prekeratinocytes, preadipocytes, and maxillofacial osteoblasts in primary cultures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108(3):341–352. https://doi.org/10.1016/j.oro.2009.04.020

25. Dohan Ehrenfest DM, Doglioli P, de Peppo GM, Del Corso M, Charrier JB (2010) Choukroun’s platelet-rich fibrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Arch Oral Biol 55(3):185–194. https://doi.org/10.1016/j.archoralbio.2010.01.004

26. Gassling V, Hedricher J, Acil Y, Purucz N, Wiltfang J, Douglas T (2013) Comparison of platelet rich fibrin and collagen as osteoblast-seeded scaffolds for bone tissue engineering applications. Clin Oral Implants Res 24(3):320–328. https://doi.org/10.1111/j.1600-0501.2011.02333.x

27. Gassling V, Douglas T, Wamke PH, Acil Y, Wiltfang J, Becker ST (2010) Platelet-rich fibrin membranes as scaffolds for periosteal tissue engineering. Clin Oral Implants Res 21(5):543–549. https://doi.org/10.1111/j.1600-0501.2009.01900.x

28. He L, Lin Y, Hu X, Zhang Y, Wu H (2009) A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108(5):707–713. https://doi.org/10.1016/j.oro.2009.06.044

29. He X, Chen WX, Ban G, Wei W, Zou J, Chen WJ, Li XY (2016) A new method to develop human dental pulp cells and platelet-rich fibrin conditioned medium. J Endod 42(11):1633–1640. https://doi.org/10.1016/j.joen.2016.08.011

30. Hong S, Chen W, Jiang B (2018) A comparative evaluation of concentrated growth factor and platelet-rich fibrin on the proliferation, migration, and differentiation of human stem cells of the apical papilla. J Endod 44(6):977–983. https://doi.org/10.1016/j.joen.2018.03.006
32. Kang YH, Jeon SH, Park JY, Chung JH, Chung YH, Chung IW, Kim ES, Chung PH (2011) Platelet-rich fibrin is a bioscaffold and reservoir of growth factors for tissue regeneration. Tissue Eng Part A 17(3-4):349–359. https://doi.org/10.1089/teng.TEA.2010.0327

33. Khurana R, Kudva PB, Husain SY (2017) Comparative evaluation of the isolation and quantification of stem cells derived from dental pulp and periodontal ligament of a permanent tooth and to assess their viability and proliferation on a platelet-rich fibrin scaffold. J Indian Soc Periodontol 21(1):16–20. https://doi.org/10.4103/jisp.jsip_182_16

34. Kim JH, Woo SM, Choi NK, Kim WJ, Kim S, Jung JY (2017) Effect of platelet-rich fibrin on odontoblastic differentiation in human dental pulp cells exposed to lipopolysaccharide. J Endod 43(3):433–438. https://doi.org/10.1016/j.joen.2016.11.002

35. Kobayashi M, Kawase T, Okuda K, Wolff LF, Yoshie H (2015) In vitro immunological and biological evaluations of the angiogenic potential of platelet-rich fibrin preparations: a standardized comparison with PRP preparations. Int J Implant Dent 1(1):31. https://doi.org/10.1186/s40729-015-0032-0

36. Schar MO, Diaz-Romero J, Kohl S, Zwiseman MA, Nesci D (2015) Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res 473(5):1635–1643. https://doi.org/10.1199/jc.11999-015-1492-2

37. Liang ZJ, Xu X, Li DQ, Liang YD, Zhu DD, Yi XL, He N, Huang YQ, Tang C, Li HM (2018) Precise intradental injection of nanofat-derived stromal cells combined with platelet-rich fibrin improves the efficacy of facial skin rejuvenation. Cell Physiol Biochem 47(1):316–329. https://doi.org/10.1159/000489800

38. Miron RJ, Fujioka-Kobayashi C, Hernandez M, Kandalam U, Zhang Y, Ghanati S, Choukroun J (2017) Injectable platelet-rich fibrin (i-PRF): opportunities in regenerative dentistry? Clin Oral Investig 21(8):2619–2627. https://doi.org/10.1007/s00784-017-2063-9

39. Kim JH, Hyun KY, Kang NH (2017) Effects of growth factors from platelet-rich fibrin on the bone regeneration. J Craniofac Surg 28(4):860–865. https://doi.org/10.1097/SCS.0000000000002396

40. Verboeket R, Herrera-Vizcaino C, Thorwart K, Booms P, Bellen M, Al-Maawi S, Sader R, Marzi I, Henrich D, Ghanati S (2019) Influence of concentration and preparation of platelet-rich fibrin on human bone marrow mononuclear cells (in vitro). Platelets 30(7):861–870. https://doi.org/10.1080/09537310.2018.1530346

41. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J (2017) Optimized platelet-rich fibrin with low-speed concept: growth factor release, biocompatibility, and cellular response. J Periodontol 88(1):112–121. https://doi.org/10.1902/jp.2016.104443

42. Passaretti F, Tia M, D’Esposito V, De Pascale M, Del Corso M, Sepulvers R, Liguoro D, Valentino R, Beguinot F, Formisano P, Sammartino G (2014) Growth-promoting action and growth factor release by different platelet derivatives. Platelets 25(4):252–256. https://doi.org/10.3109/09537310.2013.809060

43. Saeed MA, El-Rahman MA, Helal ME, Zaher AR, Grawish ME (2017) Efficacy of human platelet rich fibrin exudate vs fetal bovine serum on proliferation and differentiation of dental pulp stem cells. Int J Stem Cells 10(1):38–47. https://doi.org/10.12838/ijsc16067

44. Vahabi S, Vaziri S, Torshabi M, Rezaei Esfahrood Z (2015) Effects of plasma rich in growth factors and platelet-rich fibrin on proliferation and viability of human gingival fibroblasts. J Dent (Tehran) 12(7):504–512

45. Wang X, Zhang Y, Choukroun J, Ghanati S, Miron RJ (2018) Effects of an injectable platelet-rich fibrin on osteoblast behavior and bone tissue formation in comparison to platelet-rich plasma. Platelets 29(1):48–55. https://doi.org/10.1080/09537310.2017.1293807

46. Wang X, Zhang Y, Choukroun J, Ghanati S, Miron RJ (2017) Behavior of gingival fibroblasts on titanium implant surfaces in combination with either injectable-PRF or PRP. Int J Mol Sci 18(2). https://doi.org/10.3390/ijms18020331

47. Wei H, Gu SX, Liang YD, Liang ZJ, Chen H, Zhu MG, Xu FT, He N, Wei XJ, Li HM (2017) Nanofat-derived stem cells with platelet-rich fibrin improve facial contour remodeling and skin rejuvenation after autologous structural fat transplantation. Oncotarget 8(40):6854–68556. https://doi.org/10.18632/oncotarget.19721

48. Wirohadidjojo YW, Budiyanto A, Soebono H (2016) Platelet-rich fibrin lysate can ameliorate dysfunction of chronically UVA-irradiated human dental fibroblasts. Yonsei Med J 57(5):1282–1285. https://doi.org/10.3349/yjm.2016.57.5.1282

49. Wirohadidjojo YW, Budiyanto A, Soebono H (2015) Gelsinioside Rg1 and platelet-rich fibrin enhance human breast adipose-derived stem cell function for soft tissue regeneration. Oncotarget 7(23):35390–35403. https://doi.org/10.18632/oncotarget.9360

50. Wang X, Zhang Y, Li L, Lv X, Zhang J, Chen FM, Chen YJ (2015) Efficacy of human platelet rich fibrin exudate vs fetal bovine serum on proliferation and collagen-related protein expression of human osteoblasts. Aust Dent J 57(2):207–212. https://doi.org/10.1111/j.1834-7819.2012.01686.x

51. Xu FT, Liang ZJ, Li HM, Peng QL, Huang MH, Li de Q, Liang YD, Chi GY, Li de H, Yu BC, Huang JR (2016) Gelsinioside Rg1 and platelet-rich fibrin induce microRNA-199a expression in osteoblasts and increase osteoblast differentiation. J Endod 42(1):82–88. https://doi.org/10.1016/j.joen.2015.06.019

52. Wu CL, Lee SS, Tsai CH, Wu B, Zhao JH, Chang YC (2012) Platelet-rich fibrin increases cell attachment, proliferation and collagen-related protein expression of human osteoblasts. J Endod 38(2):207–212. https://doi.org/10.1016/j.joen.2011.11.013

53. Wu CL, Lee SS, Tsai CH, Wu B, Zhao JH, Chang YC (2012) Platelet-rich fibrin increases cell attachment, proliferation and collagen-related protein expression of human osteoblasts. Aust Dent J 57(2):207–212. https://doi.org/10.1111/j.1834-7819.2012.01686.x

54. Gervois P, Ratajczak J, Wolfs E, Ghanati S, Al-Maawi S, Booms P, Ratajczak M, Girish CS, Muller HD, Gruber R (2019) Platelet-rich fibrin suppresses in vitro osteoclastogenesis. J Periodontol.https://doi.org/10.1002/JPER.19-00109

55. Gomez TW, Gopal RV, Gaffoor FMA, Kumar STR, Girish CS, Muller HD, Gruber R (2019) Comparative evaluation of angiogenesis using a novel platelet-rich product: an in vitro study. J Conser Dent 22(1):23–27. https://doi.org/10.4103/JCD.JCD_216_18

56. Herrera-Vizcaino C, Dohele O, Al-Maawi S, Booms P, Sader R, Kirkpatrick CJ, Choukroun J, Ghanati S (2019) Platelet-rich fibrin secretome induces three dimensional angiogenic activation in vitro. Eur Cell Mater 37:250–264. https://doi.org/10.22203/eCM.v037a15

57. Kargarpour Z, Nasirzade J, Strauss FJ, Di Summa F, Hasannia S, Muller HD, Gruber R (2019) Platelet-rich fibrin suppresses in vitro osteoclastogenesis. J Periodontol.https://doi.org/10.1002/JPER.19-00109

58. Kasnak G, Fleita D, Jaatinen O, Kononen E, Tunali M, Gursoy M, Gursoy UK (2019) Regulatory effects of PRF and titanium surfaces on cellular adhesion, spread, and cytokine expressions of gingival keratinocytes. Histochem Cell Biol 152(1):63–73. https://doi.org/10.1007/s00418-019-01774-8

59. Li X, Yang H, Zhang Z, Yan Z, Lv H, Zhang Y, Wu B (2018) Platelet-rich fibrin exudate promotes the proliferation and osteogenic differentiation of human periodontal ligament cells in vitro. Mol Med Rep 18(5):4477–4485. https://doi.org/10.3892/mmr.2018.9472
60. Mahendran K, Kottuppallil G, Sekar V (2019) Comparative evaluation of radiopacity and cytotoxicity of platelet-rich fibrin, platelet-rich fibrin + 50wt% nano-hydroxyapatite, platelet-rich fibrin + 50wt% dentin chips: An in vitro study. J Conserv Dent 22(1):28-33. https://doi.org/10.4103/jcd.jcd_281_18

61. Mudalal M, Sun X, Li X, Zhou Y (2019) The evaluation of leukocyte-platelet rich fibrin as an anti-inflammatory autologous biological additive. A novel in vitro study. Saudi Med J 40(7): 657–668. https://doi.org/10.15537/smj.2019.7.24302

62. Qin Y, Tang S, Zhen G, Ding Q, Ding S, Cao X (2018) Bone-targeted delivery of TGF-beta type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati-Engelmann disease. Ann N Y Acad Sci 1433(1):29–40. https://doi.org/10.1111/nyas.13941

63. Ratajczak J, Vangassewinkel T, Gervois P, Mercck G, Hilkens P, Quirynen M, Lambrecht I, Bronckaers A (2018) Angiogenic properties of ‘leukocyte- and platelet-rich Fibrin”. Sci Rep 8(1):14632. https://doi.org/10.1038/s41598-018-29396-8

64. Steller D, Herbst N, Pries R, Juhl D, Hakim SG (2019) Positive impact of platelet-rich plasma and platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid. Sci Rep 9(1):8310. https://doi.org/10.1038/s41598-019-43798-z

65. Wang X, Yang Y, Zhang Y, Miron RJ (2019) Fluid platelet-rich fibrin stimulates greater dermal skin fibroblast cell migration, proliferation, and collagen synthesis when compared to platelet-rich plasma. J Cosmet Dermatol. https://doi.org/10.1111/jocd.12955

66. Steller D, Herbst N, Pries R, Juhl D, Klinger M, Hakim SG (2019) Impacts of platelet-rich fibrin and platelet-rich plasma on primary osteoblast adhesion onto titanium implants in a biphosphonate in vitro model. J Oral Pathol Med. https://doi.org/10.1111/jop.12944

67. Moradian H, Rafiee A, Ayatollahi M (2017) Design and fabrication of a novel transplant combined with human bone marrow mesenchymal stem cells and platelet-rich fibrin: new horizons for periodontal tissue regeneration after dental trauma. Iran J Pharm Res 16(4):1370–1378

68. Elgamal A, Althani AA, Abd-Elmaksoud A, Kassab M, Farag A, Lashen S, Gabr MM, Zakaria MM, Ismail HEA, Elgamal A, Galil A, Caceci T, Cencircelli CC, Marei HE (2019) Xeno-free trans-differentiation of adipose tissue-derived mesenchymal stem cells into fetal and neuronal cells. Am J Stem Cells 8(2): 38–51

69. Nasirzade J, Kargarpour Z, Hasannia S, Strauss FJ, Gruber R (2019) Platelet-rich fibrin elicits an anti-inflammatory response in macrophages in vitro. J Periodontol. https://doi.org/10.1002/jper.19-0216

70. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329–333. https://doi.org/10.1038/nprot.2007.30

71. Boydén S (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115: 453–466. https://doi.org/10.1084/jem.115.5.453

72. Park JS, Pabst AM, Ackermann M, Moegel M, Jung J, Kasaj A (2018) Biofunctionalization of porcine-derived collagen matrix using enameled matrix derivative and platelet-rich fibrin: influence on mature endothelial cell characteristics in vitro. Clin Oral Investig. 22(2):909–917. https://doi.org/10.1007/s00784-017-2170-7

73. Stein GS, Lian JB (1993) Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endoher Rev 14(4):424–442. https://doi.org/10.1210/edrv-14-4-424

74. ChangYC, Zhao JH (2011) Effects of platelet-rich fibrin on human periodontal ligament fibroblasts and application for periodontal inflammation defects. Aust Dent J 56(4):365–371. https://doi.org/10.1111/j.1834-7819.2011.01362.x

75. Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ (2016) Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 20(9):2353–2360. https://doi.org/10.1007/s00784-016-1719-1

76. Miron RJ, Xu H, Chai J, Wang J, Zheng S, Feng M, Zhang X, Wei Y, Chen Y, Mourao C, Sculean A, Zhang Y (2019) Comparison of platelet-rich fibrin (PRF) produced using 3 commercially available centrifuges at both high (~700 g) and low (~200 g) relative centrifugal forces. Clin Oral Investig. https://doi.org/10.1007/s00784-019-02981-2

77. Tsujino T, Takahashi A, Yamaguchi S, Watanabe T, Isobe K, Kitamura Y, Tanaka T, Nakata K, Kawase T (2019) Evidence for contamination of silica microparticles in advanced platelet-rich fibrin matrices prepared using silica-coated plastic tubes. Biomedicines 7(2). https://doi.org/10.3390/biomedicines7020045

78. Miron R, Choukroun J, Ghanati, A. (2018) Controversies related to scientific report describing g-forces from studies on platelet-rich fibrin: necessity for standardization of relative centrifugal force values. International Journal of Growth Factors and Stem Cell in Dentistry

79. Pinto N, Quirynen M (2018) Letter to the editor regarding Fujikyo-Kobayashi et al. 2017 (JOP-16-0443.R1). J Periodontol. https://doi.org/10.1002/jper.18-0175

80. Antoniades HN, Scher CD, Stiles CD (1979) Purification of human platelet-derived growth factor. Proc Natl Acad Sci U S A 76(4): 1809–1813. https://doi.org/10.1073/pnas.76.4.1809

81. Tsukamoto T, Matsu T, Fukase M, Fujita T (1991) Platelet-derived growth factor B chain homodimer enhances chemotaxis and DNA synthesis in normal osteoblast-like cells (MC3T3-E1). Biochem Biophys Res Commun 175(3):745–751. https://doi.org/10.1016/0006-291x(91)91629-q

82. Noda M, Rodan GA (1986) Type-beta transforming growth factor inhibits proliferation and expression of alkaline phosphatase in murine osteoblast-like cells. Biochem Biophys Res Commun 140(1):56–65. https://doi.org/10.1016/0006-291x(86)91057-0

83. Inagaki Y, Truter S, Ramirez F (1994) Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem 269(20):14828–14834

84. Verrecchia F, Mauviel A (2007) Transforming growth factor-beta and fibrosis. World J Gastroenterol 13(22):3056–3062. https://doi.org/10.3748/wjg.v13.i22.3056

85. Trindade R, Albrektsson T, Galli S, Prgomet Z, Tengvall P, Wennerberg A (2018) Osseointegration and foreign body reaction: titanium implants activate the immune system and suppress bone resorption during the first 4 weeks after implantation. Clin Implant Dent Relat Res 20(1):82–91. https://doi.org/10.1111/cid.12578

86. Kumar A, Mahendra J, Samuel S, Govindraj J, Loganathan T, Vashum Y, Mahendra L, Krishnamoorthy T (2019) Platelet-rich fibrin/biphasic calcium phosphate impairs osteoclast differentiation and promotes apoptosis by the intrinsic mitochondrial pathway in chronic periodontitis. J Periodontol 90(1):61–71. https://doi.org/10.1002/jper.17-0306

87. Castro AB, Herrera ER, Slomka V, Pinto N, Teughels W, Quirynen M (2019) Antimicrobial capacity of leucocyte-and platelet rich fibrin: necessity for standardization of relative centrifugal force values. International Journal of Growth Factors and Stem Cell in Dentistry

88. Hamzacebi B, Oduncuoglu B, Alaaddinoglu EE (2015) Treatment of periodontal ligament fibroblasts and application for periodontal therapy. Ann Periodontics Restorative Dent 20(1):82–91. https://doi.org/10.1111/j.1834-7819.2011.01362.x
damage and division of Staphylococcus aureus. FASEB J 32(7): 3707–3716. https://doi.org/10.1096/fj.201701190R

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.